Innoplexus

Innoplexus is a company based in Frankfurt am Main, Germany. Evidence linked to the Innoplexus identity describes Partex.AI, an AI-powered therapeutic asset accelerator that applies big data and artificial intelligence to drug discovery and development, and lists Dr. Gunjan Bhardwaj as Founder and Chief Executive Officer. Partex.AI's product line includes Ontosight® ADMETron, Ontosight® AI, and Ontosight® Asset42.

Innoplexus is a company based in Frankfurt am Main, Germany. Evidence associated with the Innoplexus identity describes Partex.AI, an AI-powered therapeutic asset accelerator that applies big data and artificial intelligence to drug discovery and development. Partex.AI states that it is incubating three promising drug assets in oncology within focused SPVs, and that pharma and biotech partners work with it to unlock value from deprioritized or off-strategy assets. Its leadership team includes Dr. Gunjan Bhardwaj as Founder and Chief Executive Officer and Gaurav Tripathi as Co-Founder & Chief Technology Officer.

AI-powered therapeutic asset accelerator for drug discovery and development

• Ontosight® ADMETron

  Enables fast, accurate prediction of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET/Tox) properties directly from SMILES input.

• Ontosight® AI

  An AI partner in research delivering citation-backed answers from biomedical literature, patents, and clinical data.

• Ontosight® Asset42

  An AI-powered drug asset exchange platform designed to identify and revive unattended and underexplored pharmaceutical assets.

1. 1Partex.AI | World's Largest AI-Powered Therapeutic Asset Acceleratorpartex.ai
2. 2Our Vision | Transforming Drug Discovery with AI | Partex.AIpartex.ai
3. 3AI Molecular Design & ADMET Prediction Tools | Partex.AIpartex.ai